{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:28:00Z","timestamp":1791350880020,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.eururo.2015.04.018","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T12:39:26Z","timestamp":1430138366000},"page":"621-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"68","author":[{"given":"Meta H.M.","family":"Diekstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epie","family":"Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodr\u00edguez-Antona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.04.018_bib0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0150","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2015.04.018_bib0155","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0160","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.04.018_bib0165","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.018_bib0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0175","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.018_bib0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"Van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2015.04.018_bib0185","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","article-title":"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity","volume":"27","author":"van Erp","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0190","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.018_bib0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2012.09.040","article-title":"Potential role of genetic markers in the management of kidney cancer","volume":"63","author":"Junker","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0200","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","article-title":"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study","volume":"12","author":"Garcia-Donas","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/1078-0432.CCR-10-1828","article-title":"Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib","volume":"17","author":"van der Veldt","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.018_bib0210","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.26491","article-title":"Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.04.018_bib0215","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2015.04.018_bib0220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a toolset for whole-genome association and population-based linkage analysis","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2015.04.018_bib0225","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.eururo.2015.04.018_bib0230","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0235","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1245\/s10434-013-3290-1","article-title":"Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"20","author":"Kwon","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2014.47","article-title":"Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662","volume":"96","author":"Diekstra","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2015.04.018_bib0245","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3109\/0284186X.2014.918276","article-title":"Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"53","author":"Beuselinck","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0250","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40262-013-0111-4","article-title":"Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study","volume":"53","author":"Kloth","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eururo.2015.04.018_bib0255","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2012.501","article-title":"VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib","volume":"108","author":"Scartozzi","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2015.04.018_bib0260","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/bjc.2012.548","article-title":"Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib","volume":"108","author":"Beuselinck","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2015.04.018_bib0265","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt.2424","article-title":"Pharmacogenomics in clinical practice and drug development","volume":"30","author":"Harper","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.04.018_bib0270","first-page":"5s","article-title":"Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC) [abstract 4503]","volume":"32","author":"Johnson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.018_bib0275","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.eururo.2015.04.018_bib0280","unstructured":"EuroTARGET: Targeted therapy in renal cell cancer: genetic and tumour related biomarkers for response and toxicity. European collaborative project funded by the European Commission under the Seventh Framework Programme (FP7). EuroTARGET Web site. http:\/\/www.eurotargetproject.eu."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:57:24Z","timestamp":1566608244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815003206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0302283815003206"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.018","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}